Holen Sie sich die Stockscreener-App
48.36
4.16%
-2.10
Handel nachbörslich:
48.51
0.15
+0.31%
Schlusskurs vom Vortag:
$50.46
Offen:
$50.72
24-Stunden-Volumen:
2.24M
Relative Volume:
0.78
Marktkapitalisierung:
$9.12B
Einnahmen:
$2.83B
Nettoeinkommen (Verlust:
$-1.02B
KGV:
-8.7768
EPS:
-5.51
Netto-Cashflow:
$194.14M
1W Leistung:
-10.94%
1M Leistung:
-8.79%
6M Leistung:
-10.87%
1J Leistung:
+3.31%
1-Tages-Spanne:
$48.32
$50.77
1-Wochen-Bereich:
$48.32
$54.85
52-Wochen-Spanne:
$39.97
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Vergleichen Sie EXAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
48.36 | 10.24B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
404.94 | 160.56B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
188.07 | 141.52B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
520.87 | 42.74B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
112.04 | 34.11B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
158.96 | 27.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
U.S. Biomarkers Market Projected to Surpass USD 106.03 Billion by 2034 | CAGR: 15.6% - industrytoday.co.uk
What analysts say about Exact Sciences Corporation stockExplosive wealth accumulation - PrintWeekIndia
What drives Exact Sciences Corporation stock priceBreakthrough investment results - PrintWeekIndia
How to Invest in Financial Technology Stocks Strategic Stock Investment PlanFree Trend-Following Techniques - jammulinksnews.com
Is Exact Sciences Corporation a good long term investmentAccelerated earnings growth - jammulinksnews.com
Top Stocks for Wealth Management AI Powered Stock Selection StrategyHigh-performance investment picks - jammulinksnews.com
Thermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know - Yahoo Finance
Canaccord Genuity reiterates Buy rating on Exact Sciences stock ahead of study - Investing.com
Envestnet Asset Management Inc. Buys 13,004 Shares of Freshpet, Inc. (NASDAQ:FRPT) - Defense World
Wall Street Analysts Think Exact Sciences (EXAS) Could Surge 26.24%: Read This Before Placing a Bet - Yahoo Finance
Exact Sciences to release Q2 2025 results on August 6 By Investing.com - Investing.com Canada
Exact Sciences to release Q2 2025 results on August 6 - Investing.com Australia
Press Release: Exact Sciences Schedules Second Quarter 2025 Earnings Call - 富途牛牛
Exact Sciences Schedules Second Quarter 2025 Earnings Call - The Globe and Mail
Cancer Screening Leader Exact Sciences Sets Q2 2025 Earnings Release DateKey Details Inside - Stock Titan
EXAS SEC FilingsExact Sciences Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Exact Sciences stock rises as Canaccord maintains Buy rating By Investing.com - Investing.com Canada
Exact’s Cancer-Screening Patent Invalidated in Geneoscopy Win - Bloomberg Law News
Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences’ ’781 Patent - Business Wire
August 29th Options Now Available For EXACT Sciences Corp. (EXAS) - Nasdaq
Exact Sciences stock rises as Canaccord maintains Buy rating - Investing.com
Exact Sciences’ Oncodetect test receives Medicare coverage By Investing.com - Investing.com Nigeria
Exact Sciences Says Its Oncodetect Test to Detect Colorectal Cancer Gets Medicare Coverage - MarketScreener
Exact Sciences’ Oncodetect test receives Medicare coverage - Investing.com Australia
Exact Sciences announces Medicare coverage for Oncodetect(TM) molecular residual disease - MarketScreener
Exact Sciences gains Medicare coverage for colorectal cancer test - StreetInsider
Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer - Business Wire
What Makes Exact Sciences (EXAS) a New Buy Stock - Yahoo Finance
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Yahoo Finance
Tom Still: Cancer tests continue to propel Exact Sciences - ehextra.com
Concerns Rise Over Exact Sciences Corp. (EXAS) Salesforce Reorganization Affecting Growth - Yahoo Finance
EXAS Shares Gain as Supreme Court Decision Clarifies Market Concerns | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Sees Positive Impact from Supreme Court Decision | EXAS Stock News - GuruFocus
Supreme Court upholds ACA’s preventive care coverage - BioWorld MedTech
The 5 Most Interesting Analyst Questions From Exact Sciences’s Q1 Earnings Call - Yahoo Finance
Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out - Benzinga
EXAS: Barclays Adjusts Price Target for Exact Sciences | EXAS Stock News - GuruFocus
QGEN vs. EXAS: Which Stock Is the Better Value Option? - Yahoo Finance
Barclays Adjusts Price Target for Exact Sciences (EXAS) in Q2 Ou - GuruFocus
Exact Sciences Expands Oncodetect Validation, Unveils MRD Innovation Roadmap. - Yahoo Finance
Inside Wisconsin: Cancer tests continue to propel Exact Sciences, even in a skeptical age - hngnews.com
Exact Sciences in Madison unveils trio of cancer detection tests - The Cap Times
Tom Still: Cancer tests continue to propel Exact Sciences, even in time of research cuts - La Crosse Tribune
Insider Sell: Katherine Zanotti Sells Shares of Exact Sciences Corp (EXAS) - GuruFocus
Exact Sciences Shareholders Approve New Incentive Plan By Investing.com - Investing.com Canada
Exact Sciences Shareholders Approve New Incentive Plan - Investing.com
Exact Sciences Corp (EXAS) Shares Gap Down to $53.95 on Jun 12 - GuruFocus
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Colorectal Cancer Screening Market Deep Research Report - openPR.com
Rhumbline Advisers Acquires 3,873 Shares of Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Hologic Climbs 13% in a Month: How Should You Play the Stock? - Yahoo Finance
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.04%
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):